

## ECCO – ESOP, Joint Symposium Essential Requirements for Quality Cancer Care

M. Skelin

The European Cancer Organisation (ECCO) has started to building up the position statement on integrated cancer care under project on Essential Requirements for Quality Cancer Care (ERQCC). Project included various healthcare experts from different fields, including the oncology pharmacist. On the meetings essential requirements were defined for each profession and for each center in general, including the essential requirements for oncology pharmacist as an external member of multi professional team for various oncology settings.

Professional team for various oncology settings.

### Essential requirements

The Oncology Pharmacist should liaise with the multi-professional team to discuss cancer specific treatments, including interactions with other treatments; should supervise the preparation of oncology drugs; and should be involved in the counselling of patients about their drug treatment.

The Oncology Pharmacists should have experience considering antineoplastic treatments and supportive care; interactions between drugs; drug dose adjustments based on age, liver and kidney function, and toxicity profile; utilization and monitoring of pharmacotherapy; patient counselling and pharmacovigilance; and knowledge of complementary and alternative medicines.

considering antineoplastic treatments and supportive care; interactions between drugs; drug dose adjustments based on age, liver and kidney function, and toxicity profile; utilization and monitoring of pharmacotherapy; patient counselling and pharmacovigilance; and knowledge of complementary and alternative medicines.

Copyright:  
ESOP  
Veritaskai 6  
21079 Hamburg  
Germany

Editor: Kleio Bourika,  
Eda Gedikoglu,  
Carolin Meier

## Yellow Hand Awards 2018

Astra Zeneca	BMS	Baxter	Celgene	Fresenius
Lilly	Medac	Mundipharma	MSD	Mylan
Omnicare	Pfizer	Puren	Sandoz	Sanofi-Aventis
Servier	Takeda	Ratiopharm	Viapharma	

## Best Poster Awards 2018

In recognition of the scientific quality, structure and organisation of the poster presentation, it is with great pleasure that the Organising and Scientific Committee of the European Society of Oncology Pharmacy (ESOP) present the Best Poster Award 2018.




## Evaluation Questionnaire

K.Bourika

As the ECOP 4 was coming to it's end, a survey was performed among the attendees. The purpose of the evaluation was to feel the pulse of the participants regarding the general organization of the ECOP. The questionnaire, which was answered by 30 participants, revealed interesting points.


The vast majority of the respondents (appr. 90%) agreed that the event was excellent or very good as an overall judgment (*Graph 1*). Also, the great majority was very pleased with the organization of the conference, as well as with the venue and it's facilities (*Graph 1*).

Graph 1



Furthermore, most of the respondents (93%) concluded that the conference was very relevant to their current work or functions and also, they evaluated the acquired information as very useful (*Graph 2*).

Graph 2



In addition, the attendees suggested other topics, which could be covered in future ECOPs, such as risk management, oral therapy, oncology in paediatrics and new drugs analysis. In conclusion, participants of the ECOP 4 had a great opportunity to reinforce their knowledge on oncology topics and exchange ideas and experiences with colleagues from all over the Europe. There is only one conclusion to be made: the ECOP 4 was crowned with success!

## Klaus Meier Award 2018

Camille Groos has been working as a hospital pharmacist since 1992, and right from the beginning he began developing special interest for oncology pharmacy, and since then he has regularly attended oncology pharmacy congresses in Germany, France and Belgium.

Camille is aware that communication and exchange of knowledge and experience with colleagues, not only in his country, but also in larger international area, is very important for improving daily work and developing new ideas for the future. Thus, it was evident for him to join ESOP as a founding member in 2000, and from that time he is acting as treasurer of the Society, an co-organising member of ECOP 1 - ECOP 4.

During all these years, Camille had the chance to meet great people and to exchange not only concerns of oncology pharmacy but also other subjects such as social and humanitarian.

He had the chance to meet colleagues, who ended up being friends!



Klaus Meier Award



Camille Groos

"In grateful appreciation of his success in creating and nurturing community relationships, of his academic contributions, of his continuous support, and in recognition of his passion, patience and tireless efforts dedicated to ESOP, it is with great pleasure that the ESOP Board and the Organising and Scientific Committee of the European Conference of Oncology Pharmacy (ECOP 2018) present the Klaus Meier Award 2018"

## Per Hartvig Honoré Award 2018

Christophe Bardin is a 57-years old pharmacist. In 2012, he earned a PhD in Pharmacology from the University of Paris V. He currently works as a clinical pharmacist at the oncology and hematology department of Cochin Hospital in Paris. He also works in pharmacology and pharmacokinetics laboratory of this hospital.

His area of research is in oncology clinical pharmacy and pharmacokinetics of antiK drugs and anti-infectious drugs.

His H-index (an international author-level metric system) is 15, corresponding to a remarkable level. He has 40 publications, while more than 1000 citations of his work can be found in the scientific literature. He published in very good journals, with high impact factor, such as Antimicrobial Agents and Chemotherapy, British Journal of Cancer, European Journal of Cancer, Annales Pharmaceutiques Françaises and numerous other journals.

He is board member of the French Society of Oncology Pharmacy (SFPO) and President of the Ethic Committee for Clinical Trials Ile de France 1.




Per Hartvig Award



Dr. Christophe Bardin

"In grateful appreciation of his tireless efforts to promote research in oncology pharmacy, of his academic contributions, of his continuous support, and in recognition of his passion, patience and dedicated to ESOP, it is with great pleasure that the ESOP Board and the Organising and Scientific Committee of the European Conference of Oncology Pharmacy (ECOP 2018) present the Per Hartvig Honoré Award 2018"



## European Conference of Oncology Pharmacy - Saturday, 27<sup>th</sup> October 2018

### Keynote Session

**B. J. Venhuis**



B.J. Venhuis


Oncology drugs clearly have become a target for pharmaceutical crime. In 2016, falsified oncology drugs ranked fifth in the most commonly falsified drug

category among the reports received by the Pharmaceutical Security Institute.

Although the prevalence of illicit oncology drugs in the legal supply chains appears to be small, these drugs are difficult to detect, particularly in clinical practice. Forthcoming countermeasures to detect illicit drugs in high-income countries include compulsory anti-tampering devices and product verification technology for a risk-based selection of medicines.

Health-care professionals must implement these new procedures into their workflow and remain vigilant about

those medicines that are not selected. Although countermeasures should firmly tighten supply chain security, there are concerns about how quickly pharmaceutical crime will adapt to these protections. Because patients and health-care professionals have shown a lenient attitude towards purchasing medicines from unreliable sources, measures against the highly accessible illegal medicine supply chain remain necessary. To improve detectability in clinical practice, reporting of ineffectiveness and unusual drug effects as adverse events or adverse drug reactions is essential.



First day of the Poster Exhibition



Coffee break in the exhibition area